Anti-tumor efficacy of SMARCA degraders in pre-clinical models of cancer

被引：0

作者：

Satyam, Leena Khare ^{[1
]}

Sasmal, Sanjita ^{[2
]}

Pothuganti, Manoj K. ^{[1
]}

Sreevidya, M. R. ^{[1
]}

Ettam, Ashokk ^{[2
]}

Nunna, Sireesha ^{[2
]}

Roshaiah, Marla ^{[2
]}

Chithaluru, Shankaraiah ^{[2
]}

Pallepati, Rangarao ^{[2
]}

Pawar, Amitkumar A. ^{[2
]}

Narukulla, Leela P. ^{[2
]}

Sripathi, Raghunadh A. ^{[2
]}

Tgore, Suraj ^{[1
]}

Nankar, Rakesh P. ^{[1
]}

Charamanna, K. B. ^{[1
]}

Gowda, Nagesh S. ^{[1
]}

Aithal, Kiran ^{[1
]}

Samiulla, D. S. ^{[1
]}

Mukherjee, Subhendu ^{[1
]}

Chelur, Shekar ^{[1
]}

Nellore, Kavitha ^{[1
]}

Daginakatte, Girish ^{[1
]}

Ramachandra, Murali ^{[1
]}

Samajdar, Susanta ^{[1
]}

机构：

[1] Aurigene Discovery Technol Ltd, Bangalore, Karnataka, India

[2] Aurigene Discovery Technol Ltd, Hyderabad, Telangana, India

来源：

CANCER RESEARCH | 2019年 / 79卷 / 13期

关键词：

D O I：

10.1158/1538-7445.SABCS18-3844

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3844

引用

页数：2

共 50 条

[1] Salinomycin: Anti-tumor activity in a pre-clinical colorectal cancer model
Klose, Johannes
Trefz, Stefan
Wagner, Tobias
Steffen, Luca
Charrier, Arsalie Preissendorfer
Radhakrishnan, Praveen
Volz, Claudia
Schmidt, Thomas
Ulrich, Alexis
Dieter, Sebastian M.
Ball, Claudia
Glimm, Hanno
Schneider, Martin
PLOS ONE, 2019, 14 (02):
[2] Anti-tumor efficacy and pre-clinical immunogenicity of IFNα2a-NGR
Zhang, Baolai
Gao, Bei
Dong, Shuhong
Zhang, Yingqi
Wu, Yongjie
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2011, 60 (01) : 73 - 78
[3] Data demonstrating the in vivo anti-tumor efficacy of thermosensitive liposome formulations of a drug combination in pre-clinical models of breast cancer
Wang, Xuehan
Regenold, Maximilian
Dunne, Michael
Bannigan, Pauric
Allen, Christine
DATA IN BRIEF, 2023, 50
[4] Anti-tumor activity of calcitriol: pre-clinical and clinical studies
Trump, DL
Hershberger, PA
Bernardi, RJ
Ahmed, S
Muindi, J
Fakih, M
Yu, WD
Johnson, CS
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2004, 89-90 (1-5): : 519 - 526
[5] The Anti-Tumor Effect of Motesanib in Pre-Clinical Models of Human Basal-Like Breast Cancer
Price, J. E.
Alvarez, R. H.
Xu, C.
Polverino, A.
Radinsky, R.
Coxon, A.
Saffran, D.
CANCER RESEARCH, 2009, 69 (24) : 784S - 784S
[6] IMMUNE ANTI-TUMOR RESPONSE IN THE PRE-CLINICAL PERIOD OF LUNG-CANCER
KOTLAR, HK
SANNER, T
EKER, P
PIHL, A
ORJASAETER, H
HARVEI, S
THEODORSEN, L
JELLUM, E
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1982, 18 (03): : 317 - 319
[7] Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model
Elie, Benelita Tina
Gocheva, Vasilena
Shree, Tanaya
Dalrymple, Stacie A.
Holsinger, Leslie J.
Joyce, Johanna A.
BIOCHIMIE, 2010, 92 (11) : 1618 - 1624
[8] Effects of Proteasome Inhibition in the Anti-Tumor Activity of Venetoclax in Mantle Cell Lymphoma Pre-Clinical Models
Kothari, Shalin K.
Mavis, Cory
Gu, Juan
Hernandez-Ilizaliturri, Francisco J.
BLOOD, 2018, 132
[9] A Novel Agent Tasquinimod Demonstrates a Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma
Ramachandran, Indu R.
Lin, Cindy
Chase, Tess
Gabrilovich, Dmitry
Nefedova, Yulia
BLOOD, 2014, 124 (21)
[10] In pre-clinical models of colorectal or head and neck carcinoma, palifermin does not alter the anti-tumor efficacy of chemotherapy or Cetuximab alone or in combination
Brake, Rachael L.
Borges, Luis
Radinsky, Robert
Starnes, Charlie
CANCER RESEARCH, 2006, 66 (08)

← 1 2 3 4 5 →